home / stock / ambs / ambs quote
Last: | $0.0001 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0001 |
Close: | $0.0001 |
High: | $0.02505 |
Low: | $0.0001 |
Volume: | 25,234 |
Last Trade Date Time: | 07/15/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0001 | $0.0001 | $0.0001 | $0.02505 | $0.0001 | 25,234 | 07-15-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 7,101 | 07-05-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 2 | 06-28-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 4,001 | 06-25-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 68,029 | 06-19-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 68,029 | 06-18-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 6,159 | 06-14-2024 |
$1e-06 | $0 | $1e-06 | $0 | $0 | 1 | 06-13-2024 |
$1e-06 | $1e-06 | $1e-06 | $0.0001 | $1e-06 | 32,000 | 06-11-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 40,000 | 06-10-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 8,300 | 05-27-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 8,300 | 05-24-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 300,401 | 05-15-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 10 | 05-10-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 200 | 05-08-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 20,801 | 05-07-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 8,267 | 05-03-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 320 | 05-01-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 100,000 | 04-29-2024 |
$1e-06 | $1e-06 | $1e-06 | $0.0001 | $1e-06 | 1,219,564 | 04-23-2024 |
News, Short Squeeze, Breakout and More Instantly...
Amarantus BioScience Holdings Inc Company Name:
AMBS Stock Symbol:
OTCMKTS Market:
Amarantus BioScience Holdings Inc Website:
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos e...